Evidence map›Paper›PMID 34550406›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2021

Additive effects of mGluR

Stephen G Nuara, Jim C Gourdon, Shawn Maddaford, Philippe Huot

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Stephen G NuaraComparative Medicine & Animal Resource Centre, McGill University, Montreal, QC, Canada.
Jim C GourdonComparative Medicine & Animal Resource Centre, McGill University, Montreal, QC, Canada.
Shawn MaddafordTalon Pharmaceuticals, Mississauga, ON, Canada.
Philippe HuotNeurodegenerative Disease Group, Montreal Neurological Institute-Hospital (The Neuro), 3801 University St, Montreal, QC, H3A 2B4, Canada. philippe.huot@mcgill.ca.ORCID http://orcid.org/0000-0002-5464-8334
McGill University · CAMontreal Neurological Institute and Hospital · CATalon Pharmaceuticals (Canada) · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAntagonising serotonin (5-HT) type 2A receptors (5-HT

methodsFive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmosets exhibiting dyskinesia and psychosis-like behaviours (PLBs) were administered L-3,4-dihydroxyphenylalanine (L-DOPA) in combination with vehicle or the 5-HT

resultsEMD-281,014 reduced dyskinesia and PLBs by up to 47% and 40%, respectively (both P < 0.001). The addition of LY-354,740, LY-487,379 and LY-354,740/LY-487,379 decreased dyskinesia by 56%, 65% and 77%, while PLBs were diminished by 55%, 63% and 71% (all P < 0.001). All treatment combinations provided anti-dyskinetic and anti-psychotic benefits significantly greater than those conferred by EMD-281,014 alone (all P < 0.05). The combination of EMD-281,014/LY-354,740/LY-487,379 resulted in anti-dyskinetic and anti-psychotic effects significantly greater than those conferred by EMD-281,014 with either LY-354,740 or LY-487,379 (both P < 0.05). No deleterious effects on L-DOPA anti-parkinsonian action were observed.

conclusionOur results suggest that combining 5-HT

Indexed as

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineAnimalsAntiparkinson AgentsBehavior, AnimalBridged Bicyclo CompoundsCallithrixDrug Therapy, CombinationDyskinesia, Drug-InducedFemaleIndolesLevodopaMaleParkinsonian DisordersPiperazinesPsychotic DisordersPyridines1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineAntiparkinson AgentsBridged Bicyclo CompoundseglumetadEMD 281014IndolesLevodopametabotropic glutamate receptor 2N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylaminePiperazinesPyridinesReceptors, Metabotropic GlutamateSerotonin 5-HT2 Receptor AntagonistsSulfonamides5-HT2ARDyskinesiaMarmosetmGluR2MPTPParkinson’s diseasePsychosis, Parkinsonism

Identifiers

PMID34550406
OpenAlexW3201587553

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.